Pan-Cancer Potential! Jiangsu Vcare’s Anti-Resistant TRK Inhibitor VC004 Capsule advances to NDA Preparation Phase
Published Time:
2025-01-26 18:06
Source:
In January 2025, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced that its self-developed next-generation anti-resistant TRK inhibitor VC004 capsule has officially entered the domestic NDA preparation phase, initiating pre-NDA communications with regulatory authorities. Marking this milestone, Jiangsu Vcare has joined the top tier of domestic self-developed drugs targeting this pathway at remarkable speed.
VC004 is clinically indicated for the treatment of NTRK fusion-positive solid tumors. It features a "tumor-agnostic" mechanism and has demonstrated outstanding efficacy and favorable safety in Phase I/II clinical studies.
The Phase I data were presented at the 2024 American Society of Clinical Oncology Annual Meeting (ASCO 2024):
In treatment-naïve patients, the confirmed objective response rate (ORR) in the recommended Phase II dose (RP2D) expansion cohort was 73.1% [95% CI: 52.2–88.4]. Among three patients who had progressed on prior TRK-TKI therapy, two showed tumor shrinkage, with one achieving a partial response (PR, 39.6%).
Most patients experienced rapid onset and sustained clinical benefits, with the longest-to-date duration of response exceeding 36 months. Among six patients with baseline brain metastases, two exhibited intracranial lesion reductions of 61.8% and 25%, respectively, while two others showed complete disappearance of non-target lesions after four months of treatment.
Safety-wise, treatment-related adverse events (TRAEs) were predominantly Grade 1–2, with no fatal TRAEs reported. No new safety signals were observed compared to other drugs in the same class.
About VC004
VC004 is a Class 1 targeted anti-tumor drug, independently developed by Jiangsu Vcare. As a next-generation TRK inhibitor with a unique anti-resistance mechanism, it is poised to become a new treatment option for patients with NTRK fusion mutations. In China, the project is advancing with a single-arm Phase II trial as the pivotal study, while its Investigational New Drug (IND) application has been approved by the US FDA. Currently, no second-generation NTRK inhibitor matches the efficacy of first-generation drugs on NTRK-naïve patients and possesses second-generation anti-drug resistance activity, positioning VC004 as a front-runner in this category.
Related News
05
2024
/
01
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced the completion of Phase II clinical enrollment for its self-developed second-generation selective JAK1 inhibitor VC005 tablets in the treatment of ankylosing spondylitis (AS). Preliminary blinded analysis from the clinical trial demonstrated favorable efficacy and safety profiles for VC005.
View Details
04
2024
/
01
Recently, Jiangsu Vcare Pharmaceutical Technology Co., Ltd. (Jiangsu Vcare) completed the first patient enrollment in the pivotal Phase II clinical trial (Registration Number: CTR20201703) in China for its self-developed next-generation TRK inhibitor, VC004. This clinical trial aims to further evaluate the efficacy and safety of VC004 in treating patients with NTRK gene fusion mutations.
View Details
03
2024
/
01
Jiangsu Vcare Submitted an NDA for Anti- platelet Drug Vicagrel to the US
Recently, Jiangsu Vcare Pharmaceutical Technology Co., Ltd. (Jiangsu Vcare) submitted an NDA to the US FDA for Vicagrel capsules for the treatment of acute coronary syndrome (ACS), ischemic stroke, and confirmed peripheral arterial disease. This marks the first NDA submission from Jiangsu Vcare's innovative drug pipeline, representing a significant milestone.
View Details
02
2024
/
01
Jiangsu Vcare Secures Over CNY 450 Million in Series C Funding
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) closed its Series C financing round, raising over CNY 450 million. The investment consortium included China Life Private Equity Investment, DYEE Capital, Hongyao Technology Capital, existing investor Nanjing Innovation Capital Group, and Hangzhou Huadian Investment.
View Details
13
2023
/
12
Jiangsu Vcare Approved to Establish "Provincial-Level Enterprise Technology Center"
Recently, the Jiangsu Provincial Department of Industry and Information Technology released the list of enterprises proposed for recognition as 2023 Provincial-Level Enterprise Technology Centers. Jiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) has been recognized as a"2023 Provincial-Level Enterprise Technology Center".
View Details
10
2023
/
11
Jiangsu Vcare's Next-Generation TRK Inhibitor VC004 Enters Pivotal Phase II Trial
Recently, the initiation of the pivotal Phase II trial for Jiangsu Vcare Pharmaceutical Technology Co., Ltd.'s (Jiangsu Vcare) next-generation TRK inhibitor VC004 project was announced at its first center, the Cancer Hospital Chinese Academy of Medical Sciences. Subsequent recruitment will take place across nearly 30 clinical centers nationwide.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn